Publications by authors named "Dennie T Frederick"

74Publications

Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy.

Immunity 2019 06 13;50(6):1498-1512.e5. Epub 2019 May 13.

Center for Immunology & Inflammatory Diseases, Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.immuni.2019.04.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527362PMC
June 2019

Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.

Nat Med 2018 Dec;24(12):1942

Center for Bioinformatics and Computational Biology, Department of Computer Science, University of Maryland, College Park, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41591-018-0247-8DOI Listing
December 2018

Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.

Nat Med 2018 10 20;24(10):1545-1549. Epub 2018 Aug 20.

Center for Bioinformatics and Computational Biology, Department of Computer Science, University of Maryland, College Park, MD, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41591-018-0157-9
Publisher Site
http://dx.doi.org/10.1038/s41591-018-0157-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693632PMC
October 2018

An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition.

J Exp Med 2017 06 27;214(6):1691-1710. Epub 2017 Apr 27.

Manchester Cancer Research Centre, Faculty of Biology, Medicine, and Health, School of Medical Sciences, Division of Molecular and Clinical Cancer Studies, The University of Manchester, Manchester M13 9PT, England, UK

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1084/jem.20160855DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460994PMC
June 2017

Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcome.

J Am Acad Dermatol 2016 Sep;75(3):595-602

Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2016.04.059DOI Listing
September 2016

Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.

Nat Med 2016 09 8;22(9):1056-61. Epub 2016 Aug 8.

Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.4155DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014622PMC
September 2016

Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance.

Cancer Discov 2016 Apr 16;6(4):382-99. Epub 2016 Mar 16.

Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts. David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts. Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087317PMC
http://dx.doi.org/10.1158/2159-8290.CD-15-0933DOI Listing
April 2016

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.

Cancer Cell 2016 Mar;29(3):270-284

Manchester Cancer Research Centre, Wellcome Trust Centre for Cell-Matrix Research, The University of Manchester, Michael Smith Building, Oxford Road, Manchester, M13 9PT, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.02.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796027PMC
March 2016

Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.

J Natl Cancer Inst 2016 Feb 23;108(2). Epub 2015 Oct 23.

Department of Medicine (PKB, RS), Department of Neurology (PKB, CMG), Department of Neurosurgery (GMS, PJ, BN, DPC, WTC, FGB), Department of Surgical Oncology (DTF), Department of Pathology (GG, DNL), Cancer Center (PKB, CMG, NN, DNL), Department of Radiology (JR) Massachusetts General Hospital, Harvard Medical School, Boston, MA; Broad Institute (ATW, GG), Department of Pathology, (MA, SS) and Department of Neurosurgery, Brigham and Women's Hospital (IFD), Boston, MA; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (DJP).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djv310DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862417PMC
February 2016

Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.

Oncotarget 2015 Dec;6(38):40535-56

Department of Biomedical Sciences and Cancer Biology Center, Texas Tech University Health Sciences Center, Amarillo, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.5755DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747351PMC
December 2015

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.

PLoS One 2015 13;10(10):e0140310. Epub 2015 Oct 13.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, United States of America; Dermatology and Cutaneous Biology Research Center, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0140310PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604168PMC
June 2016

Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients.

J Am Acad Dermatol 2015 Sep 16;73(3):491-9.e2. Epub 2015 Jul 16.

Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2015.06.006DOI Listing
September 2015

Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR.

Nat Med 2015 Jul 1;21(7):741-50. Epub 2015 Jun 1.

1] Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain. [2] Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain. [3] Institucio Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.3863DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968631PMC
July 2015

MITF Modulates Therapeutic Resistance through EGFR Signaling.

J Invest Dermatol 2015 Jul 19;135(7):1863-1872. Epub 2015 Mar 19.

Wellman Center for Photomedicine/Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; MGH Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/jid.2015.105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466007PMC
July 2015

EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.

Cancer Discov 2015 Mar 26;5(3):274-87. Epub 2014 Dec 26.

Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts. Department of Dermatology, Harvard Medical School, Boston, Massachusetts. MGH Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-14-0295DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355085PMC
March 2015

BAP1 has a survival role in cutaneous melanoma.

J Invest Dermatol 2015 Apr 18;135(4):1089-1097. Epub 2014 Dec 18.

Department of Dermatology, Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/jid.2014.528DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366338PMC
April 2015

Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma.

Cancer Res 2014 Dec 8;74(23):7037-47. Epub 2014 Oct 8.

Departments of Melanoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas. Department of Systems Biology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-1392DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4347853PMC
December 2014

The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα.

Cancer Discov 2014 Oct;4(10):1214-1229

Manchester Cancer Research Centre, Wellcome Trust Center for Cell Matrix Research, Faculty of Life Sciences, The University of Manchester, Michael Smith Building, Oxford Road, Manchester, M13 9PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-1007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184867PMC
October 2014

One Hippo and many masters: differential regulation of the Hippo pathway in cancer.

Biochem Soc Trans 2014 Aug;42(4):816-21

‡Division of Medical Oncology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, U.S.A.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1042/BST20140030DOI Listing
August 2014

A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression.

Thyroid 2014 Aug 30;24(8):1241-50. Epub 2014 Jun 30.

1 Massachusetts General Hospital , Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/thy.2013.0680DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4106380PMC
August 2014

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.

Cancer Discov 2014 Jan 21;4(1):61-8. Epub 2013 Nov 21.

1Department of Medical Oncology, Dana-Farber Cancer Institute; 2Department of Medicine, Brigham and Women's Hospital; 3Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston; 4Broad Institute of Harvard and MIT; and 5Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0631DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947296PMC
January 2014

BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes.

Oncoimmunology 2013 Oct 15;2(10):e26615. Epub 2013 Oct 15.

Department of Surgical Oncology; University of Texas MD Anderson Cancer Center; Houston, TX USA ; Department of Genomic Medicine; University of Texas MD Anderson Cancer Center; Houston, TX USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/abs/10.4161/onci.26615
Publisher Site
http://dx.doi.org/10.4161/onci.26615DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827093PMC
October 2013

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition.

Nature 2013 Dec 3;504(7478):138-42. Epub 2013 Nov 3.

1] The Broad Institute of Harvard University and Massachusetts Institute of Technology, 7 Cambridge Center, Cambridge, Massachusetts 02142, USA [2] Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA [3] Harvard Medical School, 25 Shattuck Street, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature12688DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4098832PMC
December 2013

Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.

Cancer Discov 2013 Dec 8;3(12):1378-93. Epub 2013 Oct 8.

1Tumor Metastasis and Microenvironment Program and 2Molecular and Cellular Oncogenesis Program, The Wistar Institute; 3Abramson Cancer Center, University of Pennsylvania, Philadelphia; 4Lehigh Valley Health Network, Allentown, Pennsylvania; 5The National Institute on Aging, NIH, Baltimore, Maryland; and 6Dana-Farber/Harvard Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918498PMC
December 2013

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma.

Oncoimmunology 2013 May;2(5):e24320

Division of Surgical Oncology; Massachusetts General Hospital; Boston MA USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/onci.24320DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667913PMC
May 2013

Elucidating distinct roles for NF1 in melanomagenesis.

Cancer Discov 2013 Mar 21;3(3):338-49. Epub 2012 Nov 21.

Genetics Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-12-0313DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595355PMC
March 2013